VIS832

VIS832 (0.01-10 μg/mL) efficiently binds to CD138 expressed on multiple myeloma (MM) cell lines (MM1S, MM1R, H929, U266, OPM2, RPMI8226, JJN3, MOLP8) and primary MM cells, with an affinity in the sub-nanomolar to low nanomolar range. Moreover, its binding capacity is significantly stronger than that of the anti-CD138 antibody BB4^[1].
VIS832 (0.0001-100 μg/mL) exerts potent antibody-dependent cell-mediated cytotoxicity (ADCC) against U266 multiple myeloma (MM) cells, with an EC₅₀ of approximately 99.31 ng/mL (0.66 nM). Defucosylated VIS832 shows enhanced potency, with an EC₅₀ of 28.67 ng/mL (0.2 nM) and a >7-fold increase in maximum lytic activity^[1].
VIS832 (0-10 μg/mL) induces potent, dose-dependent antibody-dependent cell-mediated cytotoxicity (ADCC) against 12 multiple myeloma (MM) cell lines, with EC₅₀ values ranging from 2.22 to 15.3 ng/mL, and the bone marrow microenvironment exerts minimal impact on this activity^[1].
VIS832 (0-10 μg/mL; 24 h) induces dose-dependent, CD138-specific autologous antibody-dependent cell-mediated cytotoxicity (ADCC) against primary multiple myeloma (MM) cells, with an EC₅₀ value of 8.58-86.04 ng/mL, and achieves a maximum lysis rate of >60% across all tested samples^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.